The yeast-derived beta-glucan ingredient has received novel food approval from the European Food Safety Authority.
The yeast-derived beta-glucan ingredient Wellmune WGP has received novel food approval from the European Food Safety Authority (EFSA; Parma, Italy), according to Biothera (Eagan, MN), the manufacturer of Wellmune WGP.
Wellmune WGP is derived from the cell walls of baker’s yeast (Saccharomyces cerevisiae). The ingredient is intended for immune health support as several published studies suggest its ability to stimulate active components of the immune system.
EFSA’s Panel on Dietetic Products, Nutrition, and Allergies stated that “Data provided on subacute and sub-chronic toxicity, absorption, and limited human data do not give reason for concern.”
The ingredient is not intended for use in infant or follow-up formulas.
EFSA’s safety decision makes Wellmune WGP the only yeast-derived beta glucan with novel food designation in Europe, says Biothera.
According to Richard Mueller, CEO of Biothera, the company is now in ongoing discussions with European companies to formulate products with Wellmune WGP.
Biothera’s European distribution partners are Immicare AB (Falkenberg, Sweden) and DKHS (Milano, Italy).